65,437 trials
Hemiplegia · Stroke, Acute · Sensory Disorders
Primary: Assessment Of Joint Position Sense — 5.0; 6.4; 8.1; 8.6 correct responses
Surgery · Sedation
Primary: Patient Satisfaction — 5.37; 5.23; 5.37; 5.05 score on a scale — p=<0.05
Halitosis · Tongue Diseases
Primary: Halitosis Measured by Organoleptic Test — 3.2; 3.2; 2.9; 1.4 score on a scale
Menorrhagia
Primary: Mean Days of Bleeding and Spotting, Spotting Only and Bleeding Only for the 84 Day Treatment Cycles and Last 28 Day Post-treatment Cycle — 29.2; 23.0; 9.3; 9.6 days…
Muscle Wasting (Atrophy) After Hip Fracture Surgery
Primary: Change From Baseline in Total Lean Body Mass Measured by DXA (Dual-energy X-ray Absorptiometry) at Weeks 12 and 24 — 1.066; 1.052; 1.059; 1.009 kg — p=<.0001
Stroke, Acute
Primary: Modified Rankin Scale (mRS) at 90 Days — 112; 68 Participants
Migraine
Primary: Number of Subjects With Any Treatment-emergent Adverse Events (TEAE) Over 12 Months — 323 Participants
Vaccination
Primary: ELISA Seropositivity Rate — 40.9; 100.0 percentage of subjects
Obesity
Primary: Child BMI — 23.3; 25.17 kg/m^2
Hyperkalemia
Primary: Least Square Mean S-K Level on Days 8-29 — 4.811; 4.381; 5.321 mmol/L — p=<0.001
Dental Caries
Primary: ROC Using the Area Under the Curve (AUC) — 0.5427; 0.5173 probability
Cardiovascular Disease · Interventional Cardiology
Primary: Number of Participants With BARC Type 2, 3, or 5 — 141; 250 Participants
Seasonal Allergic Rhinitis
Primary: Change From Baseline in Average AM/PM Reflective Total Nasal Symptom Score (rTNSS) Over Days 1 to 14. — 1.861; 1.600 score on a scale
Heart Failure
Primary: Percentage of Participants With Clinically Relevant Hypotension up to 6 Hours After the End of Study Drug Infusion — 8.3; 20.4; 18.3; 21.1 Percentage of participants
HIV Infections
Primary: Differences in Gene Expression Profiles Obtained at Baseline and Week 4 and Week 24. — 1.44 -fold TNF downregulation